RedHill Biopharma: Oral Opaganib Reduces Mortality in Severe Covid-19
February 07 2022 - 11:16AM
Dow Jones News
By Michael Dabaie
RedHill Biopharma Ltd. said an analysis showed its oral opaganib
reduces mortality by 70% given on top of remdesivir and
corticosteroids in severe Covid-19.
The company said its prespecified analysis of Phase 2/3 opaganib
data in severe Covid-19 patients showed a significant, 70.2%
mortality benefit with opaganib by day 42 when given on top of the
best available standard-of-care, remdesivir and
corticosteroids.
A second analysis showed that opaganib also delivered a
significant 34% benefit in time to recovery by day 14, with 37.4%
of opaganib-treated patients reaching this event versus 27.9% of
patients treated with placebo plus standard of care.
RedHill said it is advancing regulatory discussions in multiple
countries, with potential emergency and marketing authorization
applications being planned for certain countries in the first half
of 2022.
Write to Michael Dabaie at michael.dabaie@wsj.com
(END) Dow Jones Newswires
February 07, 2022 11:01 ET (16:01 GMT)
Copyright (c) 2022 Dow Jones & Company, Inc.
Redhill Biopharma (NASDAQ:RDHL)
Historical Stock Chart
From Mar 2024 to Apr 2024
Redhill Biopharma (NASDAQ:RDHL)
Historical Stock Chart
From Apr 2023 to Apr 2024
